Gozanertinib
Gozanertinib is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. Gozanertinib can occupy the ATP-binding site. Gozanertinib has significant antitumor efficacy[1].
Product Specifications
CAS Number
1226549-49-0
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dbpr112.html
Concentration
10mM
Purity
98.37
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=CC(C2=C(C3=CC=CC=C3)OC4=NC=NC(N[C@@H](C5=CC=CC=C5)CO)=C42)=C1)/C=C/CN(C)C
Molecular Formula
C32H31N5O3
Molecular Weight
533.62
References & Citations
[1]Lin SY, et al. Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. J Med Chem. 2019 Nov 27;62 (22) :10108-10123.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
EGFR/ErbB1/HER1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC682363-100 1x 100 µL
FOLH1 / PSMA (Prostate Epithelial Marker) (FOLH1/2363), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
LY427838 100 µg
HSBP1L1 (NM_001136180) Human Over-expression Lysate
Sign In for Pricing
View Details 